Patented therapeutic approaches targeting LRP/LR for cancer treatment.

Clicks: 447
ID: 65323
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #1 of 25 articles by views in expert opinion on therapeutic patents

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
: The ubiquitously expressed 37 kDa/67 kDa high-affinity laminin receptor (laminin receptor precursor/laminin receptor, LRP/LR) is a protein found to play several roles within cells. The receptor is located in the nucleus, cytosol and the cell surface. LRP/LR mediates cell proliferation, cell adhesion and cell differentiation. As a result, it is seen to enhance tumour angiogenesis as well as invasion and adhesion, key steps in the metastatic cascade of cancer. Recent findings have shown that LRP/LR is involved in the maintenance of cell viability through apoptotic evasion, allowing for tumour progression. Thus, several patented therapeutic approaches targeting the receptor for the prevention and treatment of cancer have emerged.: The several roles that LRP/LR plays in cancer progression as well as an overview of the current therapeutic patented strategies targeting LRP/LR and cancer to date.: Small molecule inhibitors, monoclonal antibodies and small interfering RNAs might act used as powerful tools in preventing tumour angiogenesis and metastasis through the induction of apoptosis and telomere erosion in several cancers. This review offers an overview of the roles played by LRP/LR in cancer progression, while providing novel patented approaches targeting the receptor as potential therapeutic routes for the treatment of cancer as well as various other diseases.
Reference Key
vania2019patentedexpert Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vania, Leila;Morris, Gavin;Otgaar, Tyrone C;Bignoux, Monique J;Bernert, Martin;Burns, Jessica;Gabathuse, Anne;Singh, Elvira;Ferreira, Eloise;Weiss, Stefan Ft;
Journal expert opinion on therapeutic patents
Year 2019
DOI
10.1080/13543776.2019.1693543
URL
Keywords
Cancer nanoparticles metastasis apoptosis antibody therapy angiogenesis telomerase laminin receptor precursor/laminin receptor small interfering rna

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.